Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays

Reuters

2025/07/08

<a href="https://laohu8.com/S/MDCX">Medicus Pharma Ltd.</a> Seeks FDA Fast-Track Approval for Innovative Skin <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a> with Dissolvable Doxorubicin Microneedle Arrays

Medicus Pharma Ltd. has announced the submission of a Type C meeting request to the U.S. Food and Drug Administration (FDA) as part of its efforts to fast-track the clinical development program for treating Basal Cell Carcinoma $(BCC)$ of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA). The meeting, anticipated for the week of October 6th, 2025, aims to discuss the D-MNA product development and secure the FDA's consent to accelerate the clinical pathway. The company is seeking the FDA's feedback on various aspects, including the selected doses for future studies and the appropriateness of the primary endpoint for upcoming trials. This development is a significant step in Medicus Pharma's ongoing regulatory review process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 258042) on July 08, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2549627541"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549627541\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549627541?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549627541","market":"nz","top_or_hot":-1,"title":"Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Seeks FDA Fast-Track Approval for Innovative Skin <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a> with Dissolvable Doxorubicin Microneedle Arrays\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced the submission of a Type C meeting request to the U.S. Food and Drug Administration (FDA) as part of its efforts to fast-track the clinical development program for treating Basal Cell Carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a> of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA). The meeting, anticipated for the week of October 6th, 2025, aims to discuss the D-MNA product development and secure the FDA's consent to accelerate the clinical pathway. The company is seeking the FDA's feedback on various aspects, including the selected doses for future studies and the appropriateness of the primary endpoint for upcoming trials. This development is a significant step in <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a>'s ongoing regulatory review process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 258042) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-08 19:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Seeks FDA Fast-Track Approval for Innovative Skin <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a> with Dissolvable Doxorubicin Microneedle Arrays\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced the submission of a Type C meeting request to the U.S. Food and Drug Administration (FDA) as part of its efforts to fast-track the clinical development program for treating Basal Cell Carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a> of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA). The meeting, anticipated for the week of October 6th, 2025, aims to discuss the D-MNA product development and secure the FDA's consent to accelerate the clinical pathway. The company is seeking the FDA's feedback on various aspects, including the selected doses for future studies and the appropriateness of the primary endpoint for upcoming trials. This development is a significant step in <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a>'s ongoing regulatory review process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 258042) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL3zr5Md:1","article_id":"2549627541","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549627541","pubTimestamp":1751974291,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays. Medicus Pharma Ltd. has announced the submission of a Type C meeting request to the U.S. Food and Drug Administration  as part of its efforts to fast-track the clinical development program for treating Basal Cell Carcinoma  of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays . The meeting, anticipated for the week of October 6th, 2025, aims to discuss the D-MNA product development and secure the FDA's consent to accelerate the clinical pathway. The company is seeking the FDA's feedback on various aspects, including the selected doses for future studies and the appropriateness of the primary endpoint for upcoming trials. This development is a significant step in Medicus Pharma's ongoing regulatory review process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strive","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MDCX":"Medicus Pharma Ltd."},"translate_title":"Medicus Pharma Ltd.寻求FDA快速批准使用可溶性阿霉素微针阵列进行创新皮肤癌治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCX":0.9},"content_text":"Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays\n    \n\nMedicus Pharma Ltd. has announced the submission of a Type C meeting request to the U.S. Food and Drug Administration (FDA) as part of its efforts to fast-track the clinical development program for treating Basal Cell Carcinoma $(BCC)$ of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA). The meeting, anticipated for the week of October 6th, 2025, aims to discuss the D-MNA product development and secure the FDA's consent to accelerate the clinical pathway. The company is seeking the FDA's feedback on various aspects, including the selected doses for future studies and the appropriateness of the primary endpoint for upcoming trials. This development is a significant step in Medicus Pharma's ongoing regulatory review process.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 258042) on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}